BDSI BioDelivery Sciences Internatio

+0.20  (9%)
Previous Close 2.20
Open 2.30
Price To book 3.18
Market Cap 132.78M
Shares 55,325,000
Volume 1,105,368
Short Ratio 10.62
Av. Daily Volume 600,473

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine

Latest News

  1. Edited Transcript of BDSI earnings conference call or presentation 15-May-17 8:30pm GMT
  2. BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%
  3. BDSI CEO on Belbuca revenue potential: We're on an upward trend
  4. BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains
  5. /C O R R E C T I O N -- BioDelivery Sciences International, Inc./
  6. BioDelivery tops Street 1Q forecasts
  7. Investor Network: BioDelivery Sciences International, Inc. to Host Earnings Call
  8. BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday, May 15
  9. What's in Store for BioDelivery (BDSI) this Earnings Season?
  10. BDSI's expanded approval of opioid dependence drug required few resources, exec says
  11. BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment for Opioid Dependence
  12. BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference
  13. BioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound?
  14. New cash, patents boost optimism at Raleigh's BioDelivery Sciences
  15. BioDelivery to Grant New Patents for its Marketed Drugs
  16. Blog Coverage BioDelivery Extends its Patent Portfolio; Acquires Extended Patents for BELBUCA, BUNAVIL, and ONSOLIS
  17. BioDelivery Sciences Secures Two Patents
  18. BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS®
  19. BioDelivery Sciences International and Rexahn Pharmaceuticals See Share Values Rise Slightly
  20. BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet

SEC Filings

  1. 8-K - Current report 17847049
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17845471
  3. NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB 17830763
  4. 8-K - Current report 17805485
  5. 8-K - Current report 17730971
  6. CT ORDER - Confidential treatment order 17714954
  7. 8-K/A [Amend] - Current report 17713107
  8. 8-K - Current report 17698835
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17695193
  10. 8-K - Current report 17642808